JWH-015
JWH-015 is a chemical from the naphthoylindole family, which acts as a cannabinoid receptor type 2 (CB2) agonist. It was developed by the team led by John W. Huffman at Clemson University.
Chemistry[edit | edit source]
JWH-015 is part of the naphthoylindole family of compounds, which are known for their activity on the cannabinoid receptors. It is a CB2 agonist, meaning it binds to this receptor and produces a biological response.
Pharmacology[edit | edit source]
JWH-015 acts as a CB2 agonist. The CB2 receptor is primarily found in the immune system, and its activation results in anti-inflammatory and potentially anti-cancer effects. However, the exact mechanisms of action of JWH-015 are still under investigation.
Research[edit | edit source]
Research on JWH-015 has primarily focused on its potential therapeutic uses. Studies have suggested that it may have anti-inflammatory and anti-cancer properties, although more research is needed to confirm these findings.
See also[edit | edit source]
References[edit | edit source]
JWH-015 Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD